Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer
The primary endpoint of this study is the pathological complete response after neo-adjuvant
Erbitux-based chemotherapy followed by surgery and radiotherapy. The second endpoint of this
study is the disease free survival rates (1, 2, 3, 5 years), locoregional control rates (1,
3, 5 years), overall survival rate (3, 5 years), and the safety.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Pathological Complete Response
To evaluate pathological Complete Response (pCR) after neo-adjuvant Erbitux-based chemotherapy followed by surgery and radiotherapy.
Up to 6 months
Yes
Chen-ping Zhang, MD, PhD
Study Chair
Department of Oral and Maxillofacial Surger, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University
China: Ethics Committee
9thShanghai
NCT01434394
August 2011
February 2017
Name | Location |
---|